We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Renin Co-Crystallization to Speed Cardiovascular Drug Discovery
News

Renin Co-Crystallization to Speed Cardiovascular Drug Discovery

Renin Co-Crystallization to Speed Cardiovascular Drug Discovery
News

Renin Co-Crystallization to Speed Cardiovascular Drug Discovery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Renin Co-Crystallization to Speed Cardiovascular Drug Discovery "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Renin inhibitors are currently under development for the treatment of hypertension, chronic renal disease and congestive heart failure.

A protease produced in the kidneys, renin cleaves angiotensinogen which is ultimately converted to angiotensin II, bringing about sodium retention and an increase in blood pressure.

Inhibiting renin in hypertensive individuals may provide benefits over current therapies to reduce blood pressure, decrease salt retention and may protect organs sensitive to hypertension such as the kidney, heart and brain.

ActiveSight's "ready-to-go" Portfolio Protein crystals are designed to allow pharmaceutical and biotech companies to take advantage of protein structure based drug design in their drug development programs, even if they do not have internal structural biology capabilities.

ActiveSight have said that clients can submit their lead compounds to it where they are co-crystallized with the Portfolio Protein of interest and the structure of the complex is solved, providing important, rapid lead development data to the client.

ActiveSight is employing crystallographic-grade recombinant human renin supplied by Proteos, Inc.
Advertisement